Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Levofloxacin Injection (referred to as "the drug"). The approved indications are for mild, moderate, and severe infections caused by susceptible bacteria, including: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbation of chronic bronchitis; (5) complicated skin and skin structure infections; (6) uncomplicated skin and skin soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; and (11) inhalational anthrax (post-exposure). The drug is a self-developed chemical product by the group. As of April 2026, the group's cumulative R&D investment for the drug at this stage is approximately RMB 1.94 million (unaudited). According to the latest IQVIA CHPA data, in 2025, the sales of Levofloxacin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 1.057 billion. The approval of this drug for market launch will further enrich the group's product portfolio.